Carterra® is a leading provider of innovative technologies designed to accelerate the discovery of novel therapeutic candidates. Carterra’s high throughput LSA® instrument for monoclonal antibody (mAb) screening and characterization combines patented microfluidics technology with real-time High Throughput Surface Plasmon Resonance (HT-SPR) and industry leading Kinetic and Epitope analysis and visualization software, delivering up to 100 times the throughput in 10% of the time while using only 1% of the sample compared to existing platforms.
The LSA provides customers with screening and characterization throughput and functionality that matches the output from state-of-the-art antibody expression platforms. This enables all antibodies to be rapidly and comprehensively screened early in the discovery process so that unique epitopes and potential novel therapeutic candidates can be identified, while expanding and enhancing IP coverage. The Carterra LSA condenses months of work into a few days.
Read about Carterra in the news:
- Genovac Acquires the Carterra LSA® Instrument to Enable State-of-the-Art Antibody Screening and Characterization Services
- Carterra is streamlining the arduous process of screening new life-saving drugs, Utah Business, March 29, 2022
- Expert View: Transforming biotherapeutic development post-pandemic, Drug Target Review, Q1 2022
- More News